Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report). Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.
My favorite memento from #ACR17 in San Diego: I got my Rheumatology Secrets book (kinda) autographed by Dr. Sterling West. It reads "Good Luck in Your Career. Stop Winning Rheum Knowledge Bowls!" pic.twitter.com/GVrLOlMsRC
With ACR 2017 winding down and the sheer volume of information seemingly overwhelming, I wanted to take the time to write an article regarding a few tips I learned that I will use in clinical practice.
While the incidence of pneumocystis pneumonia (PJP) is low is patients with rheumatologic diseases the mortality is quite high compared to PJP in patients with HIV and infection can be prevented with appropriate prophylaxis. In HIV prophylaxis is guided by CD4 counts but in the rheumatology world we have nothing to guide us and there exist no formal recommendations as far as when to start/stop PJP prophylaxis.
During today’s plenary session Micheal D. George, et al. presented results of a study that sought to compare risk of post-op infections in RA patients undergoing arthroplasty exposed to biologic DMARDs versus methotrexate.
In the registration trials for febuxostat there were concerns about a cardiovascular (CV) safety signal. In studies of the effect of allopurinol on CV risk/events allopurinol has found to be protective so whether febuxostat is different is a point to clarify. So this study by MaryAnn Zhang and co-authors from Brigham & Women’s Hospital and Boston University, Boston and The Seoul National University in Korea is an important piece of work to contribute to building a picture of the CV safety of febuxostat.
Did you realize that @Twitter now allows all users to send 280-character tweets, doubling the number of allowed characters from 140? This means that you can include twice as much information in your tweets, although I don’t think longer is always better. What do you think? #ACR17
As a follow up to Dr. Will Harvey’s lecture at ACR 2017 (session title: Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS, and APMs), here are the keys for reporting your collections.
With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.
We take many things for granted. I walked 11,151 steps today going from sessions to posters and exhibit halls to learn as much as I can to take back to my clinic so I can help my patients. My feet were hurting, and my back bothered me as I tried to get comfortable for the next lecture; yet, these minor discomforts are nothing compared to what our patients experience on a daily basis.
IgG4 related fibrosis is rare condition with little data available on its diagnosis and treatment. No specific diagnostic markers were developed for this indication to date. A group of researchers from Nagasaki took an aim at identifying potential biomarker specific for IGG4 related disease (IgG4 RD).